Revolution Medicines, Inc.
RVMD
Rankning i aktier
#586
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aktiekurs
$194.60
Marknadsvärde
$41.71B
Förändring (1 dag)
-0.99%
Förändring (1 år)
263.81%
Land
US
Handel Revolution Medicines, Inc. (RVMD)
Kategori
Healthcare
Intäkter för Revolution Medicines, Inc. (RVMD)
Intäkter i Jun 2026 TTM: 0.00
Enligt Revolution Medicines, Inc. senaste finansiella rapporter är företagets nuvarande intäkter (TTM) 0.00. År 2023 hade företaget intäkter på $11.58M en minskning jämfört med intäkterna år 2022, som var $35.38M. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäktshistorik för Revolution Medicines, Inc. från 2017 till 2026
Intäkter vid slutet av varje år
| År | Intäkter | Ändra |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | $11.58M | -67.27% |
| 2022 | $35.38M | 20.38% |
| 2021 | $29.39M | -31.62% |
| 2020 | $42.98M | -14.10% |
| 2019 | $50.04M | 148.16% |
| 2018 | $20.17M | 0.00% |
| 2017 | 0.00 | 0.00% |
Intäkter för liknande företag eller konkurrenter
| Företag | Intäkter | Intäktsdifferens | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
